Aging‑associated decline in muscle eosinophils is not merely a loss of regenerative capacity but reflects a shift toward an IL‑5‑dependent senescent state that actively suppresses fibro/adipogenic progenitor (FAP)‑mediated repair. We hypothesize that persistent IL‑5 signaling in tissue‑resident eosinophils induces an autocrine loop that upregulates senescence‑associated secretory phenotype (SASP) factors (e.g., TGF‑β1, CXCL10, MMP‑9) and reduces IL‑4/IL‑13 output, thereby converting eosinophils from pro‑regenerative to pro‑fibrotic cells. Blocking IL‑5Rα on eosinophils will reverse this SASP, restore IL‑4/IL‑13 secretion, and improve muscle regeneration in aged mice.

Mechanistic Basis

• IL‑5 is essential for eosinophil progenitor expansion, maturation, survival, and activation [2].
• In young muscle, eosinophil‑derived IL‑4/IL‑13 stimulates FAPs to support myoblast proliferation [1].
• Aging reduces IL‑33 and eosinophil numbers, correlating with impaired Treg accumulation and regeneration [5].
• SASP cytokines such as TGF‑β1 promote fibroblast activation and ECM deposition, antagonizing IL‑4/IL‑13‑driven repair.
• We propose that chronic IL‑5 exposure in aging eosinophils activates STAT5 and NF‑κB pathways, driving transcriptional programs that increase SASP while suppressing GATA3‑dependent IL‑4/IL‑13 production.
• This creates a feed‑forward loop: eosinophil‑derived TGF‑β1 further stabilizes the senescent state and inhibits neighboring FAPs from adopting a pro‑regenerative phenotype.

Testable Predictions

1. Eosinophil IL‑5Rα expression increases with age in skeletal muscle, correlating with higher phospho‑STAT5 and SASP gene signatures.
2. Genetic or pharmacologic ablation of IL‑5Rα specifically in eosinophils (using eosinophil‑Cre Il5ra^fl/fl or anti‑IL‑5Rα antibody) will:
   • Decrease eosinophil SASP markers (TGF‑β1, CXCL10, MMP‑9) and increase IL‑4/IL‑13 levels.
   • Enhance FAP proliferation and shift them toward a PDGFRα^+/Sca‑1^+ regenerative phenotype.
   • Improve muscle fiber cross‑sectional area and force generation after cardiotoxin injury in aged mice.
3. Exogenous IL‑5 administration to young mice will prematurely induce eosinophil senescence markers and impair regeneration, mimicking the aged phenotype.
4. Conditioned medium from IL‑5Rα‑deficient eosinophils will rescue FAP‑mediated myoblast proliferation in vitro, whereas medium from WT aged eosinophils will inhibit it.

Experimental Approach

• Mouse models: Use Il5ra^fl/fl crossed with eosinophil‑specific Cre (Epx‑Cre or Siglec‑F‑Cre) to delete IL‑5Rα; include littermate controls. Induce muscle injury via cardiotoxin injection in young (3 mo) and aged (20 mo) mice.
• Readouts: Flow cytometry for eosinophil activation (Siglec‑F^+, CD62L^low), senescence (p16^INK4a^, SA‑β‑gal), and cytokine intracellular staining (IL‑4, IL‑13, TGF‑β1). Quantify SASP transcripts by RT‑qPCR. Assess FAP phenotype (PDGFRα^+, Sca‑1^+, Collagen1^−) and proliferation (Ki‑67). Histomorphometry for centrally nucleated fibers, fibrosis (Masson’s trichrome), and grip strength.
• In vitro: Isolate peritoneal eosinophils, culture with/without IL‑5 or anti‑IL‑5Rα, collect supernatants, and apply to FAP‑myoblast co‑cultures. Measure myoblast differentiation (MyHC^+) and FAP activation.
• Falsification: If eosinophil‑specific IL‑5Rα loss does not alter SASP cytokines, fails to increase IL‑4/IL‑13, or does not improve regeneration in aged mice, the hypothesis would be refuted, suggesting that eosinophil senescence is driven by IL‑5‑independent mechanisms.

This framework links eosinophil cytokine signaling directly to cellular senescence, offering a testable axis whereby modulating IL‑5Rα could re‑program eosinophils from saboteurs to supporters of muscle repair in sarcopenia.